Immunotherapy of rheumatoid arthritis: Past, present and future

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 2, 2005, Pages 169-176

  Sivakumar, Branavan ^a,c   Paleolog, Ewa ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Biologicals; Cytokine blockade; Rheumatoid arthritis; Therapy; TNF

Indexed keywords

ABATACEPT; ADALIMUMAB; AMG 714; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENZYME INHIBITOR; ETANERCEPT; FUMAGILLOL CHLOROACETYLCARBAMATE; GOLD; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; METHIONYL AMINOPEPTIDASE; METHIONYL AMINOPEPTIDASE INHIBITOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PPI 2458; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; BONE DESTRUCTION; BONE EROSION; CARTILAGE DEGENERATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FUNCTIONAL ASSESSMENT; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION; INFLAMMATION; INJECTION SITE REACTION; LYMPHOMA; NEUTROPENIA; NONHUMAN; OUTCOMES RESEARCH; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SKELETON RADIOGRAPHY; TISSUE STRUCTURE;

ANIMALS; ARTHRITIS, RHEUMATOID; HISTORY, 20TH CENTURY; HUMANS; IMMUNOTHERAPY;

EID: 14844303710     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Lawrence RC, Hochberg MC, Kelsey JL, McDuffie FC, Medsger TA Jr, Felts WR, Shulman LE: Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol (1989) 16(4):427-441.
2. Harris ED Jr: Pathogenesis of rheumatoid arthritis. Am J Med (1986) 80(4B):4-10.
3. Williamson SC, Feldon P: Extensor tendon ruptures in rheumatoid arthritis. Hand Clin (1995) 11(3):449-459.
4. Brown FE, Brown ML: Long-term results after tenosynovectomy to treat the rheumatoid hand. J Hand Surg Am (1988) 13(5):704-708.
5. Ertel AN: Flexor tendon ruptures in rheumatoid arthritis. Hand Clin (1989) 5(2):177-190.
6. Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O'Fallon WM, Matteson EL: Survival in rheumatoid arthritis: A population-based analysis of trends over 40 years. Arthritis Rheum (2003) 48(1):54-58.
7. Van Doomum S, McColl G, Wicks IP: Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis? Arthritis Rheum (2002) 46(4):862-873.
8. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 107(9):1303-1307.
9. Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A: Death rates and causes of death in patients with rheumatoid arthritis: A population-based study. Scand J Rheumatol (2004) 33(4):221-227.
10. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, Paimela L, Blafield H, Puolakka K, Mottonen T: Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: Five-year experience from the FIN-RACo study. Arthritis Rheum (2004) 50(7):2072-2081.
11. Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D, Wakefield RJ, Reece RJ, Miles S, Adebajo A, Gough A et al: Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum (2000) 43(8):1809-1819.
12. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol (1996) 14:397-440.
13. Feldmann M, Brennan FM, Paleolog E, Cope A, Taylor P, Williams R, Woody J, Maini RN: Anti-TNFα therapy of rheumatoid arthritis: What can we learn about chronic disease? Novartis Foundation Symposium (2004) 256:53-69. This paper, along with references [14] and [15], provides a historical perspective of immunotherapy for RA.
14. Vilcek J, Feldmann M: Historical review: Cytokines as therapeutics and targets of therapeutics. Trends Pnarmacol Sci (2004) 25(4):201-209. This paper, along with references [13] and [15] provides a historical perspective of immunotherapy for RA.
15. Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN: The transfer of a laboratory based hypothesis to a clinically useful therapy: The development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol (2004) 18(1):59-80. This paper, along with references [13] and [14], provides a historical perspective of immunotherapy for RA.
16. Di Giovine FS, Nuki G, Duff GW: Tumour necrosis factor in synovial exudates. Ann Rheum Dis (1988) 47(9):768-772.
17. Chu CQ, Field M, Feldmann M, Maini RN: Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 34(9):1125-1132.
18. Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN: Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: Implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol (1992) 31(10):653-661.
19. Deleuran BW, Chu CQ, Field M, Brennan FM, Mitchell T, Feldmann M, Maini RN: Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor a. Arthritis Rheum (1992) 35(10):1170-1178.
20. Brennan FM, Chantry D, Jackson AM, Maini RN, Feldmann M: Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun (1989) (2 Suppl):177-186.
21. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M: Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 2(8657):244-247. The first report demonstrating that JNFα blockade reduces inflammatory cytokine production by cultured RA synovial cells.
22. Butler DM, Maini RN, Feldmann M, Brennan FM: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-α antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw (1995) 6(4):225-230.
23. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M: Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-α. Eur J Immunol (1991) 21(10):2575-2579.
24. Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA (1992) 89(20):9784-9788. Demonstrates the effectiveness of TNFα blockade in a murine model of arthritis.
25. Maini RN, Taylor PC, Paleolog E, Charles P, Ballara S, Brennan FM, Feldmann M: Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis (1999) 58(Suppl 1):156-160.
26. Maini RN, Taylor PC: Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med (2000) 61:207-229.
27. Feldmann M, Maini RN: Anti-TNF α therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol (2001) 19:163-196.
28. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, MacFarlane JD, Bijl H et al: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 3M(8930):1105-1110. Results of a randomized, double-blind clinical trial of infliximab in RA.
29. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P: Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet (1999) 354(9194):1932-1939.
30. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR et al: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med (2000) 343(22):1594-1602.
31. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D, Marsters PA, Lipsky PE et al: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 50(4):1051-1065. Describes the results of a long-term study of infliximab in patients with RA.
32. Smolen J, van der Heijde D, Devogelaer J-P, Han C, Bala M, Baker D, Han J, St. Clair EW: The effect of infliximab therapy on the prevention of new erosions in patients with early rheumatoid arthritis. Arthritis Rheum (2004) 50(Suppl 9):Abs 357.
33. Moreland LW: Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol Suppl (1999) 57:7-15.
34. Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB: Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: Improvement in disability. J Rheumatol (2004) 31(8):1532-1537. Describes the results of a study of etanercept in patients with recent onset RA.
35. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum (2003) 48(1):35-45.
36. Keystone EC, Kavanaugh AF, Sharp JT, Spencer-Green GT, Perez JL, Sasso EH: Radiographic inhibition of structural damage sustained in patients with long-standing rheumatoid arthritis following 3 years of treatment with adalimumab (Humira®) plus methotrexate. Arthritis Rheum (2004) 50(Suppl 9):Abs 370. Results of a long-term study of adalimumab, which demonstrate sustained responses and joint protection for up to three years.
37. Weyand CM, Xie C, Goronzy JJ: Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. J Clin Invest (1992) 89(6):2033-2039.
38. Williams RO, Mason LJ, Feldmann M, Maini RN: Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA (1994)91(7):2762-2766.
39. Abbott JD, Moreland LW: Rheumatoid arthritis: Developing pharmacological therapies. Expert Opin Investig Drugs (2004) 13(8):1007-1018.
40. Moreland L, Weisman M, Alten R, Aranda R, Zhou Y, Wu K, Nuamah I, Becker J-C: Abatacept (CTLA4Ig) in combination with methotrexate for the treatment of rheumatoid arthritis: Favorable safety and tolerability profile sustained over 2 years. Arthritis Rheum (2004) 50(Suppl 9):Abs 1475.
41. Kremer J, Shergy N, Tindall E, Aranda R, Nuamah I, Zhou Y, Becker J-C: Sustained clinical efficacy demonstrated by the selective costimulation modulator abatacept (CTLA4Ig) In combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate. Arthritis Rheum (2004) 50(Suppl 9):Abs 351.
42. Emery P, Sheeran T, Lehane PB, Saiedabadi N, Shaw TM: Efficacy and safety of rituximab at 2 years following a single treatment in patients with active rheumatoid arthritis. Arthritis Rheum (2004) 50(Suppl 9):Abs 1762.
43. Dinarello CA: Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol (2004) 4(4):378-385. Review of IL-1 blockade in RA.
44. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I et al: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 41(12):2196-2204.
45. Bingham CO, Genovese MC, Moreland LM, Grimes I, Parsey MV: Results of a phase II study of IL1-trap in moderate to severe rheumatoid arthritis. Arthritis Rheum (2004) 50(Suppl 9):Abs 517.
46. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P: Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum (2004) 50(5):1412-1419. Describes the lack of additional benefit of IL-1 and TNFα blockade.
47. Nishimoto N, Kishimoto T: Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol (2004) 4(4):386-391.
48. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (2004) 50(6):1761 -1769.
49. McInnes I, Martin R, Zimmerman-Gorska I, Nayiager S, Sun G, Patel A, Appleton B: Safety and efficacy of a human monoclonal antibody to IL-15 (AMG 714) in patients with rheumatoid arthritis (RA): Results from a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2004) 50(Suppl 9):Abs 527.
50. McInnes IB, Gracie JA: Interleukin-15: A new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol (2004) 4(4):392-397.
51. Smeets RL, van de Loo FA, Arntz OJ, Bennink MB, Joosten LA, van den Berg WB: Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther (2003) 10(12):1004-1011.
52. Walmsley M, Butler DM, Marinova-Mutafchieva L, Feldmann M: An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis. Immunology (1998) 95(1):31-37.
53. Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, Feldmann M: Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum (1996) 39(3):495-503.
54. Sivakumar B, Harry LE, Paleolog EM: Modulating angiogenesis: More versus less. J Am Med Assoc (2004) 292(8):972-977. Discusses angiogenesis as a potential therapeutic target in RA.
55. Harry LE, Paleolog EM: From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. Birth Defects Res Part C Embryo Today (2003) 69(4):363-374.
56. Peacock DJ, Banquerigo ML, Brahn E: Angiogenesis inhibition suppresses collagen arthritis. J Exp Med (1992) 175(4):1135-1138.
57. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E: The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatol (1998) 25(5):964-969.
58. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E: Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: Reduction of vascular endothelial growth factor (VEGF). Cell Immunol (1995) 166(2):196-206.
59. de Bandt M, Grossin M, Weber AJ, Chopin M, Elbim C, Pla M, Gougerot-Pocidalo MA, Gaudry M: Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum (2000) 43(9):2056-2063.
60. Bernier SG, Lazarus DD, Clark E, Doyle B, Labenski MT, Thompson CD, Westlin WF, Hannig G: A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci USA (2004) 101(29):10768-10773.
61. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA: Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist. J Clin Invest (1999) 103(1):47-54.
62. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E: Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest (2000) 80(8):1195-1205.
63. Lu J, Kasama T, Kobayashi K, Yoda Y, Shiozawa F, Hanyuda M, Negishi M, Ide H, Adachi M: Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol (2000) 154(11):5922-5927.
64. Afuwape AO, Feldmann M, Paleolog E: Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther (2003) 10(23):1950-1960.
65. Kaiser MJ, Bozonnat MC, Jorgensen C, Daures JP, Sany J: Effect of etanercept on tenosynovitis and nodules in rheumatoid arthritis. Arthritis Rheum (2002) 46(2):559-560.